Holen Sie sich die Stockscreener-App
0.5186
3.76%
0.0188
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$0.4998
Offen:
$0.4957
24-Stunden-Volumen:
1.24M
Relative Volume:
0.63
Marktkapitalisierung:
$117.33M
Einnahmen:
$9.10M
Nettoeinkommen (Verlust:
$-82.47M
KGV:
-0.8941
EPS:
-0.58
Netto-Cashflow:
$-72.32M
1W Leistung:
+24.81%
1M Leistung:
+50.80%
6M Leistung:
-14.68%
1J Leistung:
-42.17%
1-Tages-Spanne:
$0.48
$0.5285
1-Wochen-Bereich:
$0.39
$0.54
52-Wochen-Spanne:
$0.285
$1.07
Vaxart Inc Stock (VXRT) Company Profile
Firmenname
Vaxart Inc
Sektor
Branche
Telefon
(650) 550-3500
Adresse
170 HARBOR WAY, SUITE 300, SOUTH SAN FRANCISCO, CA
Vergleichen Sie VXRT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VXRT
Vaxart Inc
|
0.5141 | 92.43M | 9.10M | -82.47M | -72.32M | -0.58 |
|
ONC
Beigene Ltd Adr
|
236.32 | 25.21B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.18 | 112.83B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.285 | 40.72M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.67 | 62.15B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
74.07 | 5.75B | 0 | -153.72M | -103.81M | -2.00 |
Vaxart Inc Stock (VXRT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-15 | Eingeleitet | Oppenheimer | Outperform |
| 2021-12-29 | Fortgesetzt | Jefferies | Buy |
| 2021-11-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-06-29 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2021-06-24 | Eingeleitet | Jefferies | Buy |
| 2021-06-11 | Eingeleitet | Piper Sandler | Overweight |
| 2020-08-12 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-13 | Eingeleitet | B. Riley FBR | Buy |
Alle ansehen
Vaxart Inc Aktie (VXRT) Neueste Nachrichten
Vaxart Approves Resolutions to Narrow Proposed Reverse - GlobeNewswire
Vaxart seeks approval for reverse stock split to retain Nasdaq listing By Investing.com - Investing.com South Africa
Vaxart Limits Reverse Stock Split To 1-for-20 In Response To Shareholder Feedback - Nasdaq
Vaxart Board Approves Reverse Split Proposal - TipRanks
Vaxart seeks approval for reverse stock split to retain Nasdaq listing - Investing.com Nigeria
Vaxart signals cash runway into Q1 2026 while advancing COVID-19 and norovirus vaccine programs - MSN
Vaxart (VXRT) Eyes Reverse Stock Split to Secure Nasdaq Listing | VXRT Stock News - GuruFocus
Vaxart Approves Resolutions to Narrow Proposed Reverse Split Range and Proposes Reducing Authorized Shares at Future Stockholder Meeting | VXRT Stock News - GuruFocus
Vaxart Makes Last-Minute Changes to Reverse Split PlanCritical Nasdaq Deadline Approaches - Stock Titan
Vaxart gets nod to expand COVID-19 pill vaccine trial By Investing.com - Investing.com South Africa
Vaxart, Inc. Receives BARDA Approval to Initiate Dosing in 10,000-Participant Portion of Phase 2B Covid-19 Trial - marketscreener.com
Vaxart (VXRT) Secures BARDA Approval for Next Phase of COVID-19 Vaccine Trial | VXRT Stock News - GuruFocus
Vaxart Receives BARDA Approval for Phase 2b Trial - TipRanks
Vaxart gets nod to expand COVID-19 pill vaccine trial - Investing.com Australia
Vaxart Receives BARDA Approval to Initiate Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial - GlobeNewswire
Revolutionary Oral COVID Pill Vaccine Gets $460M BARDA Backing for Massive 10,000-Patient Trial - Stock Titan
Vaxart (VXRT) Rises After Positive Trial Results for Norovirus V - GuruFocus
Vaxart Publishes Positive, Complete Data from a Phase 2b - GlobeNewswire
Vaxart stock climbs on positive study of pill-based norovirus vaccine - MSN
Vaxart (VXRT) Unveils Promising Results from Phase 2b Norovirus Vaccine Study | VXRT Stock News - GuruFocus
Vaxart (VXRT) Appoints New CFO Amid Leadership Change | VXRT Sto - GuruFocus
Vaxart Publishes Positive, Complete Data from a Phase 2b Challenge Study of its First-Generation Oral Pill Norovirus Vaccine Candidate in Science Translational Medicine - The Manila Times
Revolutionary Oral Pill Vaccine Reduces Norovirus Infection by 30% in Landmark Phase 2b Trial - Stock Titan
Vaxart, Inc. (NASDAQ:VXRT) Q1 2025 Earnings Call Transcript - Insider Monkey
Vaxart Inc (VXRT) Q1 2025 Earnings Call Highlights: Strategic Progress Amidst Challenges - Yahoo Finance
Vaxart Inc Q1 2025 Earnings: EPS of -$0.10 and Revenue of $9.55 Million Meet Estimates - GuruFocus
Vaxart Reports Q1 2025 Progress and Financials - TipRanks
Vaxart (VXRT) Advances COVID-19 and Norovirus Vaccine Trials - GuruFocus
Vaxart Q1 2025 Earnings Call Transcript - MarketBeat
Vaxart Q1 Net Loss Narrows, Revenue Rises; Jeroen Grasman Named CFO - marketscreener.com
Vaxart Appoints Jeroen Grasman as New CFO - TipRanks
Vaxart Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Vaxart appoints Jeroen Grasman as new CFO - Investing.com Australia
Vaxart appoints Jeroen Grasman as new CFO By Investing.com - Investing.com Nigeria
Vaxart Provides Business Update and Reports First Quarter 2025 Financial Results - GlobeNewswire
Vaxart, Inc. SEC 10-Q Report - TradingView
Vaxart Unlocks $460M COVID Vaccine Trial Funding, Reports Strong Pipeline Progress in Q1 2025 - Stock Titan
Vaxart Appoints Jeroen Grasman as Chief Financial Officer - GlobeNewswire
Vaxart (VXRT) Proposes Reverse Stock Split to Maintain Nasdaq Li - GuruFocus
Vaxart Proposes Reverse Stock Split to Avoid Delisting - TipRanks
Vaxart, Inc. Encourages Stockholders to Approve Reverse Stock Split Proposal to Maintain Nasdaq Listing - Nasdaq
Vaxart Addresses Frequently Asked Questions on Reverse Stock Split Proposal in Definitive Proxy Statement - GlobeNewswire
'It's a mess out there': More biotech layoffs mean stiff competition for jobs at emerging companies - The Business Journals
Vaxart Resumes COVID-19 Vaccine Trial After Government Lift - TipRanks
Vaxart (VXRT) Advances Vaccine Efforts Amid Market Challenges | - GuruFocus
Vaxart seeks stockholder approval for reverse split - Investing.com
Vaxart seeks stockholder approval for reverse split By Investing.com - Investing.com Australia
Vaxart CEO Issues Letter to Stockholders Highlighting Company Progress - The Manila Times
Finanzdaten der Vaxart Inc-Aktie (VXRT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.78%
1.61%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):